Sequential immunotherapy with tofacitinib and low-dose IL-2 induces sustained remission in alopecia areata: a proof-of-concept monocentric study
Sequential tofacitinib and low-dose IL-2 therapy may reestablish immune tolerance, offering a potential strategy for drug-free remission. Larger trials are needed to confirm efficacy and optimize protocols.
Authors
- Wei Feng Shi (ORCID: https://orcid.org/0000-0001-9499-818X)
- Jundong Huang (ORCID: https://orcid.org/0000-0003-3799-6262)
- Jui-Jiun Jian (ORCID: https://orcid.org/0009-0004-6425-0882)
- Ji Li (ORCID: https://orcid.org/0000-0003-0931-5562)
- Min Li (ORCID: https://orcid.org/0000-0002-4662-4623)
- Yan Tang (ORCID: https://orcid.org/0009-0007-2368-5005)
- Zhixiang Zhao (ORCID: https://orcid.org/0009-0008-6555-1897)
- Fangfen Liu
- Ruxin Ji
- X. H. Liang
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- QJM
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1093/qjmed/hcaf221
- Citations
- 1
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.84